logo
Select company
Select metric
$ -47.12MEarnings Before Interest Taxes & Depreciation Amortization (EBITDA)
VS
Market
13
Sector
34
Industry
49
History
47
$ 10.05Close
$ 9.41 - $ 18.35 52-Week Range
Ticker Information

Ticker

SPRY

Company Name

ARS PHARMACEUTICALS INC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

ARS PHARMACEUTICALS INC - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

SPRY - EBITDA Historical data
DateDepreciation, Amortization & AccretionEarning Before Interest & Taxes (EBIT)Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)
6/30/2025$ 609K$ -47.73M$ -47.12M
3/31/2025$ 348K$ -15.36M$ -15.01M
12/31/2024$ 79K$ 8.29M$ 8.37M
9/30/2024$ 62K$ -49.1M$ -49.04M
6/30/2024$ 62K$ -44.84M$ -44.78M
3/31/2024$ 64K$ -49.7M$ -49.63M
12/31/2023$ 73K$ -54.37M$ -54.29M
9/30/2023$ -881K$ -19.95M$ -20.84M
6/30/2023$ -585K$ -22.95M$ -23.54M
3/31/2023$ -117K$ -25.01M$ -25.13M
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • ARS PHARMACEUTICALS INC's latest trailing twelve months (TTM) EBITDA stands at $ -22.42M.
  • Over the past 5 years, ARS PHARMACEUTICALS INC's average EBITDA has been $ -46.63M.
  • The median EBITDA for ARS PHARMACEUTICALS INC during this period was $ -45.95M
  • ARS PHARMACEUTICALS INC reached its highest EBITDA over the past 5 years at $ 8.37M.
  • The lowest EBITDA recorded by ARS PHARMACEUTICALS INC in the same timeframe $ -93.41M

ARS PHARMACEUTICALS INC's EBITDA vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

EBITDA Benchmarks
CompanyEBITDA
WVE : WAVE LIFE SCIENCES LTD $ -121.2MZYME : ZYMEWORKS INC $ -54.55MNAGE : NIAGEN BIOSCIENCE INC $ 19.78MCRMD : CORMEDIX INC $ 52.25MPHAT : PHATHOM PHARMACEUTICALS INC $ -256.75MURGN : UROGEN PHARMA LTD $ -134.34MGYRE : GYRE THERAPEUTICS INC $ 9.86MBEAM : BEAM THERAPEUTICS INC $ -366.93MANAB : ANAPTYSBIO INC $ -130.11MNRIX : NURIX THERAPEUTICS INC $ -225.49M

Similar metrics to EBITDA:

Definition of Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)

[Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].
EBIT + DepAmor
(=) EBITDA EBITDA for ARS PHARMACEUTICALS INC is calculated as follows: EBIT [ $ -23.97M ] + DepAmor [ $ 1.55M ]
(=) EBITDA [ $ -22.42M ]

SPRY - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA), Last 5 years

$ -93.41M

Minimum

Mar 31, 2022

$ 8.37M

Maximum

Dec 31, 2024

$ -46.63M

Average

$ -45.95M

Median

EBITDA Benchmark Analysis

 The chart above depicts the distribution of EBITDA for companies in the Total Stock Market. The average EBITDA of the companies is $ 58.79M with a standard deviation of $ 166.94M.
The following table provides additional summary stats:
EBITDA in the Market:
filtered constituents3.25K
min$ -493.3M
max$ 590.6M
average$ 58.79M
median$ 8.83M
std$ 166.94M